Super D Drug

Franchise investors often seek clarity on established brands, their operational history, and current market viability, particularly in a robust sector like pharmacies and drug stores. For those encountering the name Super D Drug, a comprehensive historical analysis is essential to understand its trajectory and why it is no longer an independent entity offering franchise opportunities today. Super D Drugs was established in 1966, with its foundational headquarters located in Memphis, Tennessee, operating as a significant regional discount drugstore chain primarily across the mid-south of the United States. The company carved out a niche under various brand names, including Super D, Ike's, and Super D Express, building a substantial presence before a series of transformative acquisitions. By 1997, Super D Drugs had expanded to 87 stores, demonstrating its regional market penetration and operational scale. The first major shift occurred on October 6, 1997, when Super D Drugs was acquired by Stephen L. LaFrance Pharmacy, a company founded by Pine Bluff pharmacist Stephen L. LaFrance in 1984. At the time of this pivotal transaction, LaFrance's company operated 15 drug stores, making the acquisition of Super D Drugs and Ike's Deep Discount Drug a strategic move that dramatically expanded its footprint. The combined entity, under Stephen L. LaFrance as president and CEO until October 20, 2006, operated stores under the USA Drug, Super D, and Ike's banners, growing to 98 locations by 2004. The ultimate change in ownership came on July 5, 2012, when Walgreens acquired USA Drug, including all Super D Drug stores, finalizing ownership on September 15, 2012. This acquisition by Walgreens, a global leader, effectively integrated Super D Drug into one of the largest pharmacy networks, signifying its transition from an independent regional franchisor to a component of a national enterprise. The broader pharmacies and drug stores industry represents a substantial and expanding market, with the global pharmacy market size estimated at USD 1.35 trillion in 2024 and projected to reach USD 2.06 trillion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.3% over that period. Another estimate places the global pharmacy market at USD 2.4 trillion in 2024, expected to grow to USD 4.1 trillion by 2035 at a 5% CAGR. Understanding the historical evolution of brands like Super D Drug within this dynamic market provides crucial context for investors evaluating current opportunities in the sector. PeerSense offers this independent, data-driven analysis, distinct from marketing collateral, to equip investors with the comprehensive intelligence needed for informed decision-making.

The pharmacies and drug stores industry stands as a robust and continuously expanding sector, attracting significant franchise investment due to its foundational role in public health and consistent demand. The global pharmacy market, valued at an estimated USD 1.35 trillion in 2024, is on a trajectory to reach USD 2.06 trillion by 2030, indicating a compelling compound annual growth rate (CAGR) of 7.3% from 2025 to 2030. An alternative projection places the global market at USD 2.4 trillion in 2024, with an anticipated surge to USD 4.1 trillion by 2035, driven by a 5% CAGR. North America notably commands a dominant position within this landscape, accounting for 53.2% of the global pharmacy market's revenue share in 2024. Within this region, the U.S. pharmacy market alone is the largest, reaching $670.5 billion in 2025 and experiencing a 2.4% increase that year. It further demonstrated a 2.7% CAGR between 2021 and 2026, with a projected increase of 3.5% in 2026, underscoring its steady expansion. The global retail pharmacy market, a specific segment within the broader industry, was valued at approximately USD 689 billion in 2023 and is anticipated to achieve USD 1693 billion by 2032, propelled by a substantial CAGR of about 10.5% between 2024 and 2032. Key consumer trends are significantly driving this growth, including the increasing prevalence of chronic diseases, which escalates healthcare spending and fuels demand for specialty drugs. The prescription segment, in particular, dominated the global pharmacy market with an 81.3% revenue share in 2024, largely due to the ongoing need for medications for chronic illnesses such as diabetes, cardiovascular diseases, and respiratory conditions. Retail pharmacies consistently held the largest revenue share in the global pharmacy industry in 2024, reflecting their central role in drug distribution. Secular tailwinds like a rising aging population and an increasing demand for home care services are further accelerating the adoption of online pharmacy services. Consumer behavior in 2022 highlighted that 57% of individuals globally utilized loyalty points for savings, and 60% valued personalized offers, indicating the critical importance of tailored customer interactions for fostering loyalty and driving sales. The competitive dynamics of this industry are characterized by the presence of major international chains such as Rite Aid Corp., CVS Health, UnitedHealth Group, Cigna, Kroger, Walmart, and Boots Walgreens, which dominate the North American retail pharmacy market, illustrating a trend toward consolidation that has absorbed regional players like the historical Super D Drug.

For prospective franchise investors, understanding the financial commitment is paramount, yet for Super D Drug, specific details regarding a current franchise opportunity, including costs, are not available because the brand as an independent franchisor is defunct. There is no evidence from the search results to indicate that "Super D Drug" itself operated as a franchised system actively seeking franchisees; the available information points to it being a corporate-owned chain that underwent significant acquisitions. Consequently, specific figures for a Super D Drug franchise fee, total investment range, liquid capital required, or net worth requirements cannot be provided for any current period. Similarly, ongoing fees such as royalty rates, advertising funds, or technology/marketing fees are not applicable to a non-active franchise system. To provide context for investors evaluating *other* pharmacy franchise opportunities, general franchise industry averages for 2025 indicate that initial franchise fees typically span from $20,000 to $50,000. Ongoing royalty fees commonly range from 4% to 8% of gross sales, although this can vary significantly, from as low as 1% to as high as 50%, depending on the specific business model and industry. For retail franchises, which include pharmacies, initial fees often fall between $10,000 and $50,000, with total investments frequently exceeding $100,000. Retail royalties typically range from 4% to 12%. The historical trajectory of Super D Drug, from its founding in 1966 to its acquisitions, provides insight into the strategic value of regional pharmacy chains. Super D Drugs was acquired by Stephen L. LaFrance Pharmacy in October 1997, a company that subsequently became part of Walgreens on July 5, 2012, with Walgreens finalizing ownership on September 15, 2012. This demonstrates how corporate backing and strategic mergers reshape market presence and investment landscapes. While Super D Drug itself is not a current franchise opportunity, the general financial considerations for pharmacy franchises involve substantial capital for inventory, regulatory compliance, professional staffing, and real estate, positioning them as mid-to-premium tier investments requiring significant capital.

Regarding the operating model and support structure, Super D Drug is not an active franchise system, meaning current details about its training programs, support structure, or territory information for prospective franchisees are not available. Historically, as a regional discount drugstore chain, Super D Drug's daily operations would have centered on efficient prescription fulfillment, management of a diverse inventory of over-the-counter medications, and potentially a selection of general merchandise, all tailored to serve its mid-south customer base. The core staffing requirements for any pharmacy operation, including those under the historical Super D Drug banners, necessitate licensed pharmacists and certified pharmacy technicians to dispense medications accurately and provide patient counseling, complemented by retail staff for front-of-store sales and customer service. Super D Drug operated under brand names such as Super D, Ike's, and Super D Express, which suggests a differentiated approach to its market segments or potentially varying store formats within its regional network. While specific details for Super D Drug are absent, general franchise ownership in the pharmacy sector typically provides franchisees with a ready-made brand and established credibility, alongside a proven business model. Franchisors in this industry often furnish targeted management training and continuous operational support, which can encompass drug distribution logistics, implementation of advanced inventory management systems, and in some cases, even the assignment of pharmacists to new branches, reducing the inherent risks associated with starting an independent pharmacy. The historical territory for Super D Drug was concentrated in the mid-south, expanding under Stephen L. LaFrance Pharmacy to cover a four-state region by 2004, including 39 stores in Arkansas, 32 in Tennessee, 18 in Mississippi, and 9 in Missouri. Eventually, the USA Drug system, which included Super D stores, grew to operate more than 160 locations across Arkansas, Oklahoma, Mississippi, Missouri, and Tennessee, indicating a strategy of regional density and market penetration. As a corporate-owned chain that underwent acquisitions, the concepts of multi-unit requirements or an owner-operator model for Super D Drug as an independent franchisor are not applicable; its growth was driven by corporate expansion and strategic consolidation rather than individual franchisee development.

For Super D Drug, Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document, which is a critical piece of information for any potential investor. A "Super D Drug" franchise profile on PeerSense, dated March 6, 2026, explicitly states "Item 19 Not Disclosed" in its FDD. This means that no specific information on average revenue per unit, median revenue, or profit margins for Super D Drug franchisees is available for analysis. Franchisors are not legally mandated to provide these disclosures, and their absence can stem from various factors, including the system being too nascent, unit-level financial results not being sufficiently compelling to attract buyers, or a strategic decision by the franchisor to avoid specific accountability for earnings claims. Despite the lack of specific Super D Drug franchise performance data, the broader industry provides a valuable financial context. The global pharmacy market, a sector Super D Drug once significantly contributed to regionally, was estimated at USD 1.35 trillion in 2024 and is projected to reach USD 2.06 trillion by 2030, reflecting a robust 7.3% CAGR. The U.S. pharmacy market alone, where Super D Drug primarily operated, was valued at $670.5 billion in 2025, experiencing a 2.4% increase that year and a 2.7% CAGR between 2021 and 2026. The retail pharmacy market specifically was valued at approximately USD 689 billion in 2023 and is anticipated to reach USD 1693 billion by 2032, with a substantial CAGR of about 10.5%. Super D Drug's historical market position as a regional discount drugstore chain suggests an operational model focused on competitive pricing and volume sales, a common strategy within the discount segment of the retail pharmacy industry. Its acquisition by Stephen L. LaFrance Pharmacy in 1997, when Super D had 87 stores compared to LaFrance's 15, indicates a strong regional presence and potentially attractive underlying unit-level performance or market share that made it a valuable acquisition target. Prior to this 1997 acquisition, Super D Drug had 87 stores. By 2004, the combined entity operating under the USA Drug, Super D, and Ike's banners had grown to 98 locations, and eventually, the USA Drug system, including Super D Drug stores, operated more than 160 stores. This growth under subsequent corporate ownership, even in the absence of Item 19 data, implies a positive trajectory for the underlying store assets and their operational viability within the consolidating market.

The growth trajectory of Super D Drug, while not as an independent franchisor, reflects significant expansion and strategic evolution within the regional pharmacy landscape. Prior to its acquisition in 1997, Super D Drug had established a network of 87 stores. Following its acquisition by Stephen L. LaFrance Pharmacy, the combined entity, operating under the USA Drug, Super D, and Ike's banners, saw its unit count expand to 98 locations by 2004, distributed across a four-state region: 39 stores in Arkansas, 32 in Tennessee, 18 in Mississippi, and 9 in Missouri. This demonstrates an initial growth phase through strategic acquisition and subsequent organic expansion under new ownership. The USA Drug system, which encompassed the Super D Drug stores, eventually operated more than 160 stores across five states, including Arkansas, Oklahoma, Mississippi, Missouri, and Tennessee, showcasing substantial regional penetration. The most significant "recent news" pertaining to Super D Drug involves these corporate developments rather than individual franchise growth. Super D Drugs was acquired by Stephen L. LaFrance Pharmacy in October 1997. Subsequently, USA Drug, along with its Super D Drug stores, was acquired by Walgreens on July 5, 2012, with Walgreens finalizing ownership on September 15, 2012. This acquisition marked a pivotal moment, as Walgreens subsequently announced plans to close 76 USA Drug affiliated stores by November 2012, indicating a strategic consolidation and integration into a larger national network. Historically, Super D Drug's competitive moat would have been built upon its strong brand recognition as a regional discount drugstore chain in the mid-south, coupled with an established network of 87 stores by 1997. This local market saturation and consumer loyalty were key assets that made it an attractive acquisition target. The brand's ultimate integration into Walgreens reflects a broader industry trend towards consolidation, where smaller regional players are absorbed by national giants to leverage greater purchasing power, achieve supply chain efficiencies, and enhance brand recognition on a larger scale. The industry continues to adapt to market conditions through digital transformation, with the growth of e-pharmacies driven by increased internet usage and consumer demand for reduced healthcare costs, even as concerns about illegal sales of unapproved drugs arise.

As Super D Drug is not an active franchise system, the concept of an "ideal franchisee" in the traditional sense does not apply. However, for those considering opportunities in the broader pharmacy franchise sector, the ideal candidate typically possesses strong management acumen, a deep understanding of retail operations, and a commitment to stringent regulatory compliance. Experience in the healthcare or pharmaceutical industry, though not always mandatory, can be highly beneficial given the specialized nature of the business. The operation of a pharmacy franchise demands meticulous attention to detail, particularly in areas like drug distribution, inventory management, and patient care, often requiring an owner-operator model due to the inherent complexities and responsibilities. Historically, Super D Drug focused its operations as a regional discount drugstore chain in the mid-south. Its territory, under Stephen L. LaFrance Pharmacy ownership by 2004, included 39 stores in Arkansas, 32 in Tennessee, 18 in Mississippi, and 9 in Missouri, eventually expanding the USA Drug system to over 160 stores across Arkansas, Oklahoma, Mississippi, Missouri, and Tennessee. This geographical concentration indicates a strategic emphasis on dominating specific regional markets through a dense network of locations. Since Super D Drug is not offering new franchise opportunities, specific timelines from signing to opening, multi-unit requirements, or details on available territories are not applicable. Similarly, franchise agreement term lengths, renewal terms, or considerations for transfer and resale are not relevant for a brand that underwent corporate acquisitions in 1997 and 2012, which represents a different scale of business transfer compared to individual franchise resales. The ultimate absorption of Super D Drug into Walgreens underscores the dynamic nature of the retail pharmacy market and the consolidation trends that shape regional presence into national footprints.

While Super D Drug is no longer an independent entity offering franchise opportunities, its historical journey provides invaluable insights for investors evaluating the dynamic pharmacies and drug stores market. The industry itself presents a compelling investment thesis, with the global pharmacy market projected to reach USD 2.06 trillion by 2030, growing at a robust 7.3% CAGR, and the U.S. market alone valued at $670.5 billion in 2025. This sustained growth is primarily driven by the increasing prevalence of chronic diseases, an aging population, and evolving consumer demands for accessible healthcare. Investors must acknowledge the significant consolidation trends exemplified by Super D Drug's acquisitions by Stephen L. LaFrance Pharmacy in 1997 and subsequently by Walgreens in 2012, which highlight the strategic importance of scale and integration in this sector. The FPI Score for Super D Drug is 48 (Fair), indicating that while the brand had historical market presence, its current status as a non-franchising entity means traditional franchise performance metrics are not applicable. The absence of current Item 19 financial performance data for Super D Drug further underscores the critical importance of comprehensive due diligence when evaluating any active franchise opportunity in the pharmacy sector. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data for active brands, and side-by-side comparison tools, empowering investors to make informed decisions in this complex market. Explore the complete Super D Drug franchise profile on PeerSense to access the full suite of independent franchise intelligence data.